Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anika Therapeutics reports strong Q4 earnings, eyes growth opportunities

Anika Therapeutics delivered strong financial performance in Q4 2022, with revenue growth and strategic investments driving growth targets for 2023. The company is focused on product launches, expanding its portfolio, and preparing for the launch of the RevoMotion Reverse Shoulder System.
While facing challenges such as higher stock-based compensation and lower EBITDA expected in 2023, Anika remains optimistic about the value inflection point in 2023. The company's emphasis on growth initiatives and commercial optimization positions it for future opportunities.

Anika Therapeutics reports growth in core segments and strategic investments

Anika Therapeutics showed positive revenue growth in Q1, driven by core business segments.
Despite a net loss, Anika is strategically positioning itself as a global leader in joint preservation.
Investments in new products and regulatory progress with Cingal indicate a focus on innovation and expansion.
Maintaining strong gross margins amidst increased operating expenses highlights operational efficiency.

Anika Therapeutics posts robust Q2 results, eyes growth opportunities

Anika Therapeutics reported strong Q2 results, raising its revenue outlook for 2023.
Despite international challenges, the company sees opportunities for growth in key segments.
Progress in FDA approvals, partnerships, and new product launches position Anika for future success.
Maintaining a focus on innovation and market expansion will be crucial for sustained growth.

Anika Therapeutics raises guidance on strong Q3 performance and outlook

Anika Therapeutics showcased robust growth in key segments, leading to an optimistic outlook for the year. Despite challenges in restructuring sales operations, the company is well-positioned for continued success with a focus on profitability and new product launches.

Anika Therapeutics exceeds Q4 expectations, eyes Hyalofast's U.S. potential

Anika Therapeutics delivered robust financial performance, focusing on driving new products for growth and operational efficiency. The company aims to accelerate profitability targets and is on track with product launches, making strategic adjustments based on feedback.

Anika Therapeutics reports Q1 revenue growth and strategic product advancements

Anika Therapeutics demonstrated solid financial performance in Q1 2024, driven by revenue growth, cost reduction initiatives, and positive market feedback on key products.
While facing challenges such as FDA approval requirements and leadership transition, the company's strengths in product portfolio and distribution agreements position it well for future growth.
Opportunities in FDA designations, revenue growth expectations, and operational improvements present avenues for Anika to enhance market presence and financial performance in the coming quarters.

Anika Therapeutics reports Q3 revenue, focuses on core products

Anika Therapeutics faces challenges with workforce reduction and financial losses
However, strategic focus on core HA products and revenue reclassification show promise
Opportunities lie in revenue growth in the commercial channel and long-term investments
Overall, Anika Therapeutics aims for sustainable growth and value creation

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

Alamo Group

A-Mark Precious Metals

AMRK, ANIK and ALG have been added to the Zacks Rank #5 (Strong Sell) List on November 11, 2024.

New Strong Sell Stocks for November 11th

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development and IR Cheryl Blanchard - President and CEO Steve Griffin - EVP, CFO and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome to Anika's Third Quarter Earnings Conference Call. [Operator Instructions].

Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript

WEST BRIDGEWATER, Mass. , Oct. 31, 2024 /PRNewswire/ -- Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ: ANIK).

Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics

Anika Therapeutics (ANIK) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.30. This compares to loss of $0.45 per share a year ago.

Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates

Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds

Anika Reports Third Quarter 2024 Financial Results

Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile

Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical

BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

Anika Announces Third Quarter 2024 Results Conference Call Date

BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 6,350 shares of common stock at a per share exercise price of $24.27, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Therapeutics, Inc (NASDAQ:ANIK ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations Cheryl Blanchard - President and Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Company Harrison Parsons - Stephens Mike Petusky - Barrington Research Operator Good afternoon, ladies and gentlemen, and welcome to Anika's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President, Investor Relations, ESG and Corp. Communications.

Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript

Anika Therapeutics (ANIK) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.19 per share a year ago.

Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates

Expanded Regenerative Solutions portfolio with full market release of the Integrity™  Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand

Anika Reports Second Quarter 2024 Financial Results

BEDFORD, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Thursday, August 15, 2024. Anika will host a virtual presentation with Q&A starting at 11:30am ET.

Anika to Participate in the Sidoti Virtual Investor Conference

BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2024 financial results after the close of the market on Thursday, August 8, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio

Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs

Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments

Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research

Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program

Anika Enters into Cooperation Agreement with Caligan Partners

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2024 Earnings Conference Call May 8, 2024 5:30 PM ET Company Participants Mark Namaroff - Vice President of Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michael Levitz - Executive Vice President and Chief Financial Officer Conference Call Participants George Sellers - Stephens Inc. James Sidoti - Sidoti & Company, LLC Mike Petusky - Barrington Research Operator Good evening, ladies and gentlemen, and welcome to Anika's First Quarter 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.

Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript

Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024

Anika Announces CFO Transition

Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2024.

Anika Reports First Quarter 2024 Financial Results

BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2024 financial results after the close of the market on Wednesday, May 8, 2024 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.

Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024

BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024. Anika will host a virtual presentation with Q&A starting at 2:15pm ET.

Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript

Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives providing annualized savings of approximately $10 million Anika positioned to generate adjusted EBITDA1 of $25 to $30 million in 2024, up over 75% at the midpoint, representing an adjusted EBITDA1 margin of at least 15% BEDFORD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its fourth quarter and full year ended December 31, 2023.

Anika Reports Fourth Quarter and Year-End 2023 Financial Results

BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the close of the market on Wednesday, March 13, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024

Announcing the limited market release of X-Twist™ Fixation System with biocomposite suture anchor for rotator cuff and other soft tissue repair at AAOS

Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting

News for Anika Therapeutics Stock (ANIK)